(NASDAQ: WVE) Wave Life Sciences's forecast annual revenue growth rate of 15.89% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 33.61%, and while it is forecast to beat the US market's average forecast revenue growth rate of 13.79%.
Wave Life Sciences's revenue in 2026 is $71,798,000.On average, 17 Wall Street analysts forecast WVE's revenue for 2026 to be $11,491,433,166, with the lowest WVE revenue forecast at $7,201,936,819, and the highest WVE revenue forecast at $19,997,898,609. On average, 17 Wall Street analysts forecast WVE's revenue for 2027 to be $11,243,455,376, with the lowest WVE revenue forecast at $37,706,475, and the highest WVE revenue forecast at $30,501,845,353.
In 2028, WVE is forecast to generate $23,878,202,745 in revenue, with the lowest revenue forecast at $527,890,657 and the highest revenue forecast at $84,839,569,857.